Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study

IF 2.3 4区医学 Q2 DERMATOLOGY

Journal of Cosmetic Dermatology Pub Date : 2025-02-27 DOI:10.1111/jocd.70078

Aditya K. Gupta, Mary A. Bamimore, Julien Seneschal, Vincent Piguet, Mesbah Talukder

{"title":"Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study","authors":"Aditya K. Gupta, Mary A. Bamimore, Julien Seneschal, Vincent Piguet, Mesbah Talukder","doi":"10.1111/jocd.70078","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Vitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta-analysis has investigated the relative effect of vitiligo on relevant monotherapies.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>The current study determined the relative effect of monotherapies for vitiligo through network meta-analyses (NMAs).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The peer-reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors (JAKIs), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve (SUCRA) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event (AE) at 6 months.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>No significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A (PUVA) and narrow band ultraviolet B (NB-UVB) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.</p>\n </section>\n </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"24 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.70078","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cosmetic Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Vitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta-analysis has investigated the relative effect of vitiligo on relevant monotherapies.

Aim

The current study determined the relative effect of monotherapies for vitiligo through network meta-analyses (NMAs).

Methods

The peer-reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.

Results

The retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors (JAKIs), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve (SUCRA) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event (AE) at 6 months.

Conclusions

No significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A (PUVA) and narrow band ultraviolet B (NB-UVB) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cosmetic Dermatology DERMATOLOGY-

CiteScore

4.30

自引率

13.00%

发文量

818

审稿时长

>12 weeks

期刊介绍： The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques. The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.